Results 41 to 50 of about 16,441 (147)

Anticoagulant treatment: the end of the old agents?

Swiss Medical Weekly, 2012
New oral anticoagulants used as single target inhibitors of coagulation enzymes have been developed and tested in extensive trial programmes. Results of most of these trials showed non-inferior and/or superior efficacy and safety compared to ...
Lukas Graf, Dimitrios A Tsakiris
doaj   +1 more source

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Clinical and Applied Thrombosis/Hemostasis, 2019
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD   +7 more
doaj   +1 more source

Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation

Journal of Arrhythmia, 2020
Introduction Recent studies have demonstrated the feasibility of uninterrupted direct oral anticoagulants (DOACs) with a temporary switch to dabigatran (“dabigatran bridge”) for atrial fibrillation (AF) ablation.
Masahide Harada, Yuji Motoike, Yoshihiro Nomura, Asuka Nishimura, Masayuki Koshikawa, Kazuhiro Murayama, Yoshiharu Ohno, Eiichi Watanabe, Hideo Izawa, Yukio Ozaki   +9 more
doaj   +1 more source

Deep vein thrombosis prophylaxis in patients who undergo knee arthroscopy: a systematic review

Knee Surgery & Related Research
Background Knee arthroscopy is one of the most common procedures performed by orthopedic surgeons. A potentially life-threatening complication following this procedure is deep vein thrombosis (DVT). DVT prophylaxis can be obtained both mechanically (e.g.,
Udit Dave, Emma G. Lewis, Victoria K. Ierulli, Shreya M. Saraf, Mary K. Mulcahey   +4 more
doaj   +1 more source

Changes in Internal Structure and Dynamics upon Binding Stabilise the Nematode Anticoagulant NAPc2

Biomolecules
Abnormal blood coagulation is a major health problem and natural anticoagulants from blood-feeding organisms have been investigated as novel therapeutics.
Elaine Woodward, Brendan M. Duggan
doaj   +1 more source

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series

Journal of Medical Case Reports, 2018
Background The lack of an antidote against factor Xa inhibitors in case of major bleeding or need for urgent surgery is a concern to clinicians. Guidelines on managing major bleeding in patients under anticoagulation with a factor Xa inhibitor suggest ...
Nina Haagenrud Schultz, Runar Lundblad, Pål Andre Holme   +2 more
doaj   +1 more source

Role of Prothrombin Complex Concentrates in Reversal of Direct Oral Anticoagulant Effects

Bezmiâlem Science
Objective: The aim of this study is to evaluate the efficacy and safety of four-factor prothrombin complex concentrate in reversing the anticoagulant effect in patients presenting to the emergency department with bleeding associated with direct oral ...
Gökhan ERSUNAN, İsmail ATAŞ, Mümin Murat YAZICI, Enes GÜLER, Özlem BİLİR   +4 more
doaj   +1 more source

Factor Xa inhibitors in hemodialysis: OK-for now! [PDF]

Proc (Bayl Univ Med Cent), 2023
Banchs JE.
europepmc   +1 more source

Reversing factor Xa inhibitors – clinical utility of andexanet alfa

Journal of Blood Medicine, 2017
Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG   +5 more
doaj  

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey

Clinical and Applied Thrombosis/Hemostasis
Direct oral factor Xa inhibitors are replacing vitamin K-dependent antagonists as anticoagulation treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications.
Charles Fasanya MD, FRCS FACS, Abenámar Arrillaga MD FACS FCCP, Catherine Caronia MD, MBA, Lauren Rothburd BS, Tenzing Japhe BA, Younghee Hahn BS, Paul Joseph BS, Dajana Reci BA, Patricia Eckardt PhD, RN, FAAN   +8 more
doaj   +1 more source